{"id":1264,"date":"2026-04-27T09:28:18","date_gmt":"2026-04-27T08:28:18","guid":{"rendered":"https:\/\/imafungi.org\/?post_type=product&p=1264"},"modified":"2026-04-27T09:36:30","modified_gmt":"2026-04-27T08:36:30","slug":"3g-ketamine-nasal-spray-ml","status":"publish","type":"product","link":"https:\/\/imafungi.org\/?product=3g-ketamine-nasal-spray-ml","title":{"rendered":"3g Ketamine Nasal Spray-ml"},"content":{"rendered":"

3g <\/em>Ketamine Nasal Spray-<\/span>mL<\/em>: The Complete Clinical & Patient Guide<\/span><\/h1>\n

<\/main><\/p>\n

Ketamine nasal spray<\/strong> has moved from the fringes of anesthesiology into mainstream psychiatry and pain management and for good reason. Whether you’re a patient exploring treatment-resistant depression<\/em>, a clinician evaluating compounded ketamine formulations, or a caregiver researching options, understanding what a 300 mg\/mL (commonly labeled “3g per bottle”) compounded ketamine nasal spray<\/strong> actually is and what the science says about it in 2026 is essential.<\/p>\n

This guide covers everything: mechanism of action, FDA-approved vs. compounded options, proper dosing, clinical evidence, safety considerations, and who qualifies. Let’s start from the beginning.<\/p>\n

\ud83d\udccb What does “3g Ketamine Nasal Spray” mean?<\/strong>
\nA “3g” ketamine nasal spray refers to a compounded preparation containing approximately 3 grams (3,000 mg) of ketamine<\/strong> total in the vial typically formulated at a concentration of 100\u2013300 mg\/mL<\/strong>. This is a common label used by compounding pharmacies and clinics. It is distinct from Spravato\u00ae (esketamine), the FDA-approved product, and is used under the direct supervision of a licensed prescriber.<\/div>\n

<\/p>\n

What Is Ketamine Nasal Spray?<\/h2>\n

Ketamine is a dissociative anesthetic that has been used in medicine since the 1960s. Originally developed as a surgical anesthetic, its unique pharmacological profile particularly its rapid antidepressant and analgesic effects has driven a renaissance of clinical research and, ultimately, FDA approval for psychiatric use.<\/p>\n

When delivered intranasally (through the nose), ketamine bypasses the first-pass metabolism in the liver, allowing for faster absorption into the bloodstream and quicker onset of therapeutic effects compared to oral routes. The nasal mucosa is highly vascular, making it an ideal delivery pathway for rapid-acting agents.<\/p>\n

Compounded ketamine nasal sprays including those labeled as “3g” or containing 300 mg\/mL concentrations are prepared by licensed compounding pharmacies<\/strong> based on a physician’s individualized prescription. These are not over-the-counter products; they require a valid prescription from a qualified healthcare provider.<\/p>\n

<\/p>\n

FDA-Approved vs. Compounded Ketamine Nasal Spray<\/h2>\n

This is one of the most important distinctions every patient and provider must understand.<\/p>\n\n\n\n\n\n\n\n\n\n\n
Feature<\/th>\nSpravato\u00ae (Esketamine)<\/th>\nCompounded Ketamine Spray (e.g., 300 mg\/mL)<\/th>\n<\/tr>\n<\/thead>\n
FDA Status<\/strong><\/td>\n\u2705 FDA-Approved (2019)<\/td>\n\u26a0\ufe0f Not FDA-approved; legal under compounding rules<\/td>\n<\/tr>\n
Active Ingredient<\/strong><\/td>\nEsketamine HCl (S-enantiomer)<\/td>\nRacemic ketamine (both R & S forms)<\/td>\n<\/tr>\n
Indication<\/strong><\/td>\nTreatment-resistant depression; MDD with suicidality<\/td>\nTRD, chronic pain, PTSD, anxiety (off-label)<\/td>\n<\/tr>\n
Administration<\/strong><\/td>\nIn-clinic under supervision (REMS program)<\/td>\nMay be prescribed for supervised in-home use<\/td>\n<\/tr>\n
Cost<\/strong><\/td>\n~$800\u2013$900 per session (insurance may cover)<\/td>\n~$150\u2013$400 per prescription<\/td>\n<\/tr>\n
Monitoring<\/strong><\/td>\nMandatory 2-hour post-dose monitoring<\/td>\nVaries by protocol; provider discretion<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

In 2024 and 2025, the FDA issued updated guidance on the prescribing and compounding of ketamine products, emphasizing that compounded formulations must be prescribed by qualified clinicians and should not be used recreationally or without medical supervision.<\/p>\n

\u26a0\ufe0f Important Regulatory Note<\/strong>
\nCompounded ketamine nasal spray sits in a regulated gray zone. It is legal when prepared by a 503A or 503B-registered compounding pharmacy under a valid prescription, but the FDA does not guarantee its safety, efficacy, or purity to the same standard as Spravato\u00ae. Always use compounded ketamine from an accredited pharmacy and under physician supervision.<\/div>\n

<\/p>\n

How Ketamine Works in the Brain<\/h2>\n

Ketamine’s rapid antidepressant effects have puzzled and excited neuroscientists for over two decades. Unlike traditional antidepressants that primarily target serotonin or norepinephrine, ketamine works primarily as an NMDA receptor antagonist<\/strong>.<\/p>\n

The NMDA Receptor Pathway<\/h3>\n

N-methyl-D-aspartate (NMDA) receptors are glutamate receptors central to synaptic plasticity, learning, and memory. In depression, chronic stress leads to glutamate dysregulation and synaptic loss. Ketamine blocks these receptors, triggering a cascade:<\/p>\n